KRAS-mediated repression of interferon regulatory factor 2 (IRF2) results in high expression of CXCL3, which binds to CXCR2 on myeloid-derived suppressor cells (MDSCs) and regulates the immune responses in colorectal cancers (42). This evidence concerns the gene KRAS and colorectal cancer.